TBVAC2020

Advancing tuberculosis vaccines from discovery to clinical development

TBVAC2020 Consortium

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Original languageEnglish
Article number1203
JournalFrontiers in Immunology
Volume8
Issue numberOCT
DOIs
Publication statusPublished - 2017 Oct 4

Fingerprint

Tuberculosis Vaccines
Vaccines
Information Dissemination
Research
Patient Selection
Biomarkers

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

@article{690a51dbfda5476c886b1c91b53832e4,
title = "TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development",
abstract = "TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.",
author = "{TBVAC2020 Consortium} and Kaufmann, {Stefan H.E.} and Dockrell, {Hazel M.} and Nick Drager and Ho, {Mei Mei} and Helen McShane and Olivier Neyrolles and Ottenhoff, {Tom H.M.} and Brij Patel and Danielle Roordink and Fran{\cc}ois Spertini and Steffen Stenger and Jelle Thole and Verreck, {Frank A.W.} and Ann Williams and Warwick Britton and Jamie Triccas and Claudio Counoupas and Johan Grooten and {Marie-Ange Demoitie}, Demoitie and Marta Romano and Kris Huygen and Tima, {Hermann Giresse} and Francoise Mascart and Peter Andersen and Claus Aagaard and Dennis Christensen and Morten Ruhwald and Thomas Lindenstrom and Pierre Charneau and Christophe Guilhot and Antonio Peixoto and Martine Gilleron and Isabelle Vergne and Camille Locht and Roland Brosch and Genevieve Inchauspe and {Theung Long}, {Stephane Leung} and January Weiner and Jeroen Maertzdorf and Natalie Nieuwenhuizen and Max Bastian and Stephanie Kallert and Stephen Gordon and Nadia Caccamo and Delia Goletti and Roberto Nisini and SungJae Shin and Sangnae Cho and Hyejon Lee and Ino Choi",
year = "2017",
month = "10",
day = "4",
doi = "10.3389/fimmu.2017.01203",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TBVAC2020 : Advancing tuberculosis vaccines from discovery to clinical development. / TBVAC2020 Consortium.

In: Frontiers in Immunology, Vol. 8, No. OCT, 1203, 04.10.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - TBVAC2020

T2 - Advancing tuberculosis vaccines from discovery to clinical development

AU - TBVAC2020 Consortium

AU - Kaufmann, Stefan H.E.

AU - Dockrell, Hazel M.

AU - Drager, Nick

AU - Ho, Mei Mei

AU - McShane, Helen

AU - Neyrolles, Olivier

AU - Ottenhoff, Tom H.M.

AU - Patel, Brij

AU - Roordink, Danielle

AU - Spertini, François

AU - Stenger, Steffen

AU - Thole, Jelle

AU - Verreck, Frank A.W.

AU - Williams, Ann

AU - Britton, Warwick

AU - Triccas, Jamie

AU - Counoupas, Claudio

AU - Grooten, Johan

AU - Marie-Ange Demoitie, Demoitie

AU - Romano, Marta

AU - Huygen, Kris

AU - Tima, Hermann Giresse

AU - Mascart, Francoise

AU - Andersen, Peter

AU - Aagaard, Claus

AU - Christensen, Dennis

AU - Ruhwald, Morten

AU - Lindenstrom, Thomas

AU - Charneau, Pierre

AU - Guilhot, Christophe

AU - Peixoto, Antonio

AU - Gilleron, Martine

AU - Vergne, Isabelle

AU - Locht, Camille

AU - Brosch, Roland

AU - Inchauspe, Genevieve

AU - Theung Long, Stephane Leung

AU - Weiner, January

AU - Maertzdorf, Jeroen

AU - Nieuwenhuizen, Natalie

AU - Bastian, Max

AU - Kallert, Stephanie

AU - Gordon, Stephen

AU - Caccamo, Nadia

AU - Goletti, Delia

AU - Nisini, Roberto

AU - Shin, SungJae

AU - Cho, Sangnae

AU - Lee, Hyejon

AU - Choi, Ino

PY - 2017/10/4

Y1 - 2017/10/4

N2 - TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

AB - TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

UR - http://www.scopus.com/inward/record.url?scp=85030571215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030571215&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.01203

DO - 10.3389/fimmu.2017.01203

M3 - Review article

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - OCT

M1 - 1203

ER -